25 XP   0   0   10

Pieris Pharmaceuticals Inc
Buy, Hold or Sell?

Let's analyse Pieris together

PenkeI guess you are interested in Pieris Pharmaceuticals Inc. Buy, hold or sell? I don't know! However, I do recommend doing research before doing anything. I will help you with that.

I'm going to help you getting a better view of Pieris Pharmaceuticals Inc. At the end you don't have to ask anyone for trading advice. You can make your own decision, with more confidence, the odds in your favor, backed by data.

You can find me behind Let's Analyse Together in the top-right of each section.

Get notifications about Pieris Pharmaceuticals Inc

I send you an email if I find something interesting about Pieris Pharmaceuticals Inc.

Quick analysis of Pieris (30 sec.)










What can you expect buying and holding a share of Pieris? (30 sec.)

How much money do you get?

How much money do you get?
$0.00
When do you have the money?
1 year
How often do you get paid?
0.0%

What is your share worth?

Current worth
$0.27
Expected worth in 1 year
$0.26
How sure are you?
35.0%

+ What do you gain per year?

Total Gains per Share
$-0.01
Return On Investment
-0.1%

For what price can you sell your share?

Current Price per Share
$12.00
Expected price per share
$1.975 - $
How sure are you?
50%

1. Valuation of Pieris (5 min.)




Live pricePrice per Share (EOD)

$12.00

Intrinsic Value Per Share

$-5.94 - $-5.05

Total Value Per Share

$-5.67 - $-4.78

2. Growth of Pieris (5 min.)




Is Pieris growing?

Current yearPrevious yearGrowGrow %
How rich?$26.7m$40.3m-$12m-42.6%

How much money is Pieris making?

Current yearPrevious yearGrowGrow %
Making money-$5.9m-$7.1m$1.2m21.5%
Net Profit Margin-256.0%-144.0%--

How much money comes from the company's main activities?

3. Financial Health of Pieris (5 min.)




4. Comparing to competitors in the Biotechnology industry (5 min.)




  Industry Rankings (Biotechnology)  


Richest
#541 / 1009

Most Revenue
#292 / 1009

Most Profit
#457 / 1009

Most Efficient
#660 / 1009

What can you expect buying and holding a share of Pieris? (5 min.)

Welcome investor! Pieris's management wants to use your money to grow the business. In return you get a share of Pieris.

What can you expect buying and holding a share of Pieris?

First you should know what it really means to hold a share of Pieris. And how you can make/lose money.

Speculation

The Price per Share of Pieris is $12.00. The market price reflects what other people think it is worth; not what it's really worth. Your job is to find out if the market price is fair, overpriced, or underpriced. I will help you with that.

If you buy blind, there is a 50% chance of making or losing money by selling the stock in the future. However, we can look at a few things to determine the odds in our favor:

  • The fundamentals: the financial health trends of Pieris.
  • The technials: based on market psychology, we can make a calculated estimate of what the price will do in the future. We can do this through technical analysis. We can calculate the probabilities and the expected value (millionaire math). That's called speculation.
  • The book value: what is the market price compared to it's book value.

Investing

If you really want to invest in Pieris, you will have to let go of the thought of selling in the future. If you have to sell the share for less than you bought it, it can still be a good investment. Focus on what it means to hold the stock forever:

  • You own a part of the company. The equity of this part can grow or shrink. The current Book Value per Share is $0.27. Based on the TTM, the Book Value Change Per Share is $0.00 per quarter. Based on the YOY, the Book Value Change Per Share is $-0.06 per quarter.
  • You may receive quarterly/yearly dividend in the form of additional shares.
  • You may receive quarterly/yearly dividend in the form of cash. Based on the TTM the Dividend per Share is $0.00 per quarter.
Based on historical numbers we can estimate the returns while holding a share of Pieris.

How much money are you going to get?

 MRQTTMYOY5Y10Y
 $% of Price per Share$% of Price per Share$% of Price per Share$% of Price per Share$% of Price per Share
Usd Eps-0.05-0.4%-0.06-0.5%-0.08-0.7%-0.09-0.7%-0.07-0.5%
Usd Book Value Change Per Share-0.04-0.3%0.000.0%-0.06-0.5%-0.01-0.1%0.010.1%
Usd Dividend Per Share0.000.0%0.000.0%0.000.0%0.000.0%0.000.0%
Usd Total Gains Per Share-0.04-0.3%0.000.0%-0.06-0.5%-0.01-0.1%0.010.1%
Usd Price Per Share0.18-0.41-1.77-2.45-2.74-
Price to Earnings Ratio-0.98--0.62--6.31--9.04--24.25-
Price-to-Total Gains Ratio-4.77--3.70-16.11--1.28--12.56-
Price to Book Ratio0.67-2.07-4.16-6.92-13.30-
Price-to-Total Gains Ratio-4.77--3.70-16.11--1.28--12.56-

When do you get the money?

Usd Investment
$.00
Usd Price Per Share12
Number of shares83
Gains per QuarterTrailing 12 Months5 Year
Usd Dividend Per Share0.000.00
Usd Book Value Change Per Share0.00-0.01
Usd Total Gains Per Share0.00-0.01
Gains per Quarter (83 shares)-0.25-0.55
Gains per Year (83 shares)-1.00-2.22
YearsReturn on Investment (TTM)Return on Investment (5Y)
 DividendBook Value gainTotal gainsDividendBook Value gainTotal gains
Broker costs---10---10
10-1-110-2-12
20-2-120-4-14
30-3-130-7-16
40-4-140-9-18
50-5-150-11-20
60-6-160-13-22
70-7-170-16-24
80-8-180-18-26
90-9-190-20-28
100-10-200-22-30

How sure are you?

Based on the past periods, how sure are you to get value out of your investment.

Linear %
 Trailing 12 Months3Y5 Year10 YearALLTIME
  % % % % %
Earnings Per Share1.03.00.025.0%1.011.00.08.3%1.019.00.05.0%3.037.00.07.5%3.038.00.07.3%
Book Value Change Per Share1.03.00.025.0%5.07.00.041.7%7.013.00.035.0%14.025.01.035.0%14.026.01.034.1%
Dividend per Share0.00.04.00.0%0.00.012.00.0%0.00.020.00.0%0.00.040.00.0%0.00.041.00.0%
Total Gains per Share1.03.00.025.0%5.07.00.041.7%7.013.00.035.0%14.025.01.035.0%14.026.01.034.1%

Fundamentals of Pieris

About Pieris Pharmaceuticals Inc

Pieris Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers and develops anticalin-based drugs. The company develops anticalin proteins that are low molecular-weight therapeutic proteins derived from lipocalins, which are naturally occurring low-molecular weight human proteins found in human blood plasma and other bodily fluids. Its lead respiratory Anticalin based drug candidate, elarekibep used for the treatment of asthma; and PRS-220, an oral inhaled Anticalin protein targeting connective tissue growth factor for the treatment of idiopathic pulmonary fibrosis. The company also develops PRS-344/S09501 2that consists of a PD-L1-targeting antibody and 4-1BB-targeting Anticalin proteins. It has a license and collaboration agreement with Les Laboratoires Servier and Institut de Recherches Internationales Servier, AstraZeneca AB, and Seagen Inc.; and license agreements with Technical University of Munich and Sichuan Kelun-Biotech Biopharmaceutical Co. Ltd. Pieris Pharmaceuticals, Inc. was incorporated in 2000 and is headquartered in Boston, Massachusetts.

Fundamental data was last updated by Penke on 2024-04-12 15:08:04.

Financial Health

Profitability Details
 Compared to previous yearCompared to industry
The company is making a huge loss.
Using its assets, the company is very inefficient in making profit.
Using its investors money, the company is very inefficient in making profit.
Operating Efficiency Details
 Compared to previous yearCompared to industry
The company is operating very inefficient.
The company is inefficient in keeping operating costs low.
Liquidity Details
 Compared to previous yearCompared to industry
The company is able to pay all its short-term debts.
The company is very able to pay all its short-term debts with the most liquid assets.
Solvency Details
 Compared to previous yearCompared to industry
The company is able to pay all its debts by selling its assets.
The company is just able to pay all its debts with equity.

Valuation

Valuation Details
 Compared to previous yearCompared to industry
Based on the equity, the company is underpriced.
Based on the earnings, the company is expensive.
Based on how much money comes from the company's main activities, the company is expensive.

1.1. Profitability of Pieris Pharmaceuticals Inc.

1.1. Profitability
1.1.1. Net Profit Margin

Measures how much net profit Pieris earns for each $1 of revenue.

  • Above 10% is considered healthy but always compare Pieris to the Biotechnology industry mean.
  • A Net Profit Margin of -352.9% means that $-3.53 for each $1 in revenue is generated as profit.

Let's take a look of the Net Profit Margin trends of Pieris Pharmaceuticals Inc:

  • The MRQ is -352.9%. The company is making a huge loss. -2
  • The TTM is -256.0%. The company is making a huge loss. -2
Trends
Current periodCompared to+/- 
MRQ-352.9%TTM-256.0%-96.9%
TTM-256.0%YOY-144.0%-112.0%
TTM-256.0%5Y-215.1%-40.9%
5Y-215.1%10Y11,496.0%-11,711.1%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-352.9%-200.1%-152.8%
TTM-256.0%-216.8%-39.2%
YOY-144.0%-288.3%+144.3%
5Y-215.1%-449.1%+234.0%
10Y11,496.0%-605.5%+12,101.5%
1.1.2. Return on Assets

Shows how efficient Pieris is using its assets to generate profit.

  • Above 5% is considered healthy but always compare Pieris to the Biotechnology industry mean.
  • -11.9% Return on Assets means that Pieris generated $-0.12 profit for each $1 in assets.

Let's take a look of the Return on Assets trends of Pieris Pharmaceuticals Inc:

  • The MRQ is -11.9%. Using its assets, the company is very inefficient in making profit. -2
  • The TTM is -10.1%. Using its assets, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ-11.9%TTM-10.1%-1.8%
TTM-10.1%YOY-6.8%-3.3%
TTM-10.1%5Y-7.5%-2.6%
5Y-7.5%10Y-229.2%+221.7%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-11.9%-13.3%+1.4%
TTM-10.1%-12.8%+2.7%
YOY-6.8%-11.7%+4.9%
5Y-7.5%-13.9%+6.4%
10Y-229.2%-15.7%-213.5%
1.1.3. Return on Equity

Shows how efficient Pieris is using its investors money to generate profit.

  • Above 15%-20% is considered healthy but always compare Pieris to the Biotechnology industry mean.
  • -17.1% Return on Equity means Pieris generated $-0.17 for each $1 the owners (shareholders) invested.

Let's take a look of the Return on Equity trends of Pieris Pharmaceuticals Inc:

  • The MRQ is -17.1%. Using its investors money, the company is very inefficient in making profit. -2
  • The TTM is -30.6%. Using its investors money, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ-17.1%TTM-30.6%+13.4%
TTM-30.6%YOY-19.8%-10.8%
TTM-30.6%5Y-25.0%-5.6%
5Y-25.0%10Y-26.4%+1.4%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-17.1%-16.9%-0.2%
TTM-30.6%-16.1%-14.5%
YOY-19.8%-15.1%-4.7%
5Y-25.0%-19.3%-5.7%
10Y-26.4%-20.2%-6.2%

1.2. Operating Efficiency of Pieris Pharmaceuticals Inc.

1.2. Operating Efficiency
1.2.1. Operating Margin

Measures how efficient Pieris is operating .

  • Measures how much profit Pieris makes for each $1 of sales after paying variable costs (production costs, wages, etc) but before taxes.
  • Above 15% is considered healthy but always compare Pieris to the Biotechnology industry mean.
  • An Operating Margin of -422.0% means the company generated $-4.22  for each $1 in revenue (before taxes).

Let's take a look of the Operating Margin trends of Pieris Pharmaceuticals Inc:

  • The MRQ is -422.0%. The company is operating very inefficient. -2
  • The TTM is -278.2%. The company is operating very inefficient. -2
Trends
Current periodCompared to+/- 
MRQ-422.0%TTM-278.2%-143.8%
TTM-278.2%YOY-206.2%-72.0%
TTM-278.2%5Y-228.3%-49.9%
5Y-228.3%10Y11,523.2%-11,751.6%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-422.0%-296.2%-125.8%
TTM-278.2%-232.5%-45.7%
YOY-206.2%-298.2%+92.0%
5Y-228.3%-492.1%+263.8%
10Y11,523.2%-632.4%+12,155.6%
1.2.2. Operating Ratio

Measures how efficient Pieris is keeping operating costs low.

  • Below 1 is considered healthy (always compare to Biotechnology industry mean).
  • An Operation Ratio of 5.22 means that the operating costs are $5.22 for each $1 in net sales.

Let's take a look of the Operating Ratio trends of Pieris Pharmaceuticals Inc:

  • The MRQ is 5.220. The company is inefficient in keeping operating costs low. -1
  • The TTM is 3.803. The company is inefficient in keeping operating costs low. -1
Trends
Current periodCompared to+/- 
MRQ5.220TTM3.803+1.417
TTM3.803YOY2.820+0.983
TTM3.8035Y3.232+0.571
5Y3.23210Y-74.843+78.076
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ5.2203.231+1.989
TTM3.8033.310+0.493
YOY2.8203.890-1.070
5Y3.2325.739-2.507
10Y-74.8437.876-82.719

1.3. Liquidity of Pieris Pharmaceuticals Inc.

1.3. Liquidity
1.3.1. Current Ratio

Measures if Pieris is able to pay off Short-term Debt.

  • Above 1.5 is considered healthy (always compare to Biotechnology industry mean).
  • A Current Ratio of 3.24 means the company has $3.24 in assets for each $1 in short-term debts.

Let's take a look of the Current Ratio trends of Pieris Pharmaceuticals Inc:

  • The MRQ is 3.244. The company is very able to pay all its short-term debts. +2
  • The TTM is 2.159. The company is able to pay all its short-term debts. +1
Trends
Current periodCompared to+/- 
MRQ3.244TTM2.159+1.085
TTM2.159YOY2.435-0.275
TTM2.1595Y2.986-0.827
5Y2.98610Y3.950-0.964
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ3.2443.890-0.646
TTM2.1594.173-2.014
YOY2.4355.344-2.909
5Y2.9866.126-3.140
10Y3.9506.448-2.498
1.3.2. Quick Ratio

Measures if Pieris is able to pay off Short-term Debt but only using the most liquid assets.

  • Above 1 is considered healthy but always compare Pieris to the Biotechnology industry mean.
  • A Quick Ratio of 3.47 means the company can pay off $3.47 for each $1 in debt (using most liquid assets).

Let's take a look of the Quick Ratio trends of Pieris Pharmaceuticals Inc:

  • The MRQ is 3.470. The company is very able to pay all its short-term debts with the most liquid assets. +2
  • The TTM is 2.202. The company is very able to pay all its short-term debts with the most liquid assets. +2
Trends
Current periodCompared to+/- 
MRQ3.470TTM2.202+1.268
TTM2.202YOY2.787-0.584
TTM2.2025Y3.452-1.250
5Y3.45210Y4.177-0.725
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ3.4703.514-0.044
TTM2.2023.998-1.796
YOY2.7875.380-2.593
5Y3.4526.105-2.653
10Y4.1776.404-2.227

1.4. Solvency of Pieris Pharmaceuticals Inc.

1.3. Liquidity
1.4.1. Debt to Asset Ratio

Measures how much % of Pieris assets are financed with debt.

  • Below 1 (100%) is considered healthy but always compare Pieris to Biotechnology industry mean.
  • A Debt to Asset Ratio of 0.31 means that Pieris assets are financed with 30.8% credit (debt) and the remaining percentage (100% - 30.8%) is financed by its owners/shareholders. 

Let's take a look of the Debt to Asset Ratio trends of Pieris Pharmaceuticals Inc:

  • The MRQ is 0.308. The company is very able to pay all its debts by selling its assets. +2
  • The TTM is 0.536. The company is able to pay all its debts by selling its assets. +1
Trends
Current periodCompared to+/- 
MRQ0.308TTM0.536-0.228
TTM0.536YOY0.642-0.106
TTM0.5365Y0.652-0.116
5Y0.65210Y1.578-0.927
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.3080.339-0.031
TTM0.5360.336+0.200
YOY0.6420.271+0.371
5Y0.6520.366+0.286
10Y1.5780.389+1.189
1.4.2. Debt to Equity Ratio

Measures if Pieris is able to pay off its debts by using shareholders equity.

  • Below 2 is considered healthy but always compare Pieris to the Biotechnology industry mean.
  • A Debt to Equity ratio of 44.6% means that company has $0.45 debt for each $1 in shareholders equity.

Let's take a look of the Debt to Equity Ratio trends of Pieris Pharmaceuticals Inc:

  • The MRQ is 0.446. The company is very able to pay all its debts with equity. +2
  • The TTM is 1.719. The company is just able to pay all its debts with equity.
Trends
Current periodCompared to+/- 
MRQ0.446TTM1.719-1.273
TTM1.719YOY1.833-0.115
TTM1.7195Y2.257-0.538
5Y2.25710Y2.447-0.191
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.4460.388+0.058
TTM1.7190.402+1.317
YOY1.8330.335+1.498
5Y2.2570.426+1.831
10Y2.4470.461+1.986

2. Market Valuation of Pieris Pharmaceuticals Inc

2.1. Earnings Per Share
2.1. Price to Earnings Ratio

Measures how much money you pay for each share for every $1 in earnings Pieris generates.

  • Above 15 is considered overpriced but always compare Pieris to the Biotechnology industry mean.
  • A PE ratio of -0.98 means the investor is paying $-0.98 for every $1 in earnings.

Let's take a look of the Price to Earnings Ratio trends of Pieris Pharmaceuticals Inc:

  • The EOD is -64.748. Based on the earnings, the company is expensive. -2
  • The MRQ is -0.982. Based on the earnings, the company is expensive. -2
  • The TTM is -0.617. Based on the earnings, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-64.748MRQ-0.982-63.766
MRQ-0.982TTM-0.617-0.365
TTM-0.617YOY-6.310+5.693
TTM-0.6175Y-9.041+8.424
5Y-9.04110Y-24.250+15.209
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD-64.748-2.264-62.484
MRQ-0.982-2.629+1.647
TTM-0.617-2.680+2.063
YOY-6.310-4.145-2.165
5Y-9.041-6.257-2.784
10Y-24.250-6.254-17.996
2.2. Price To Free Cash Flow Ratio

Let's take a look of the Price To Free Cash Flow Ratio trends of Pieris Pharmaceuticals Inc:

  • The EOD is -15.100. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The MRQ is -0.229. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The TTM is -0.867. Based on how much money comes from the company's main activities, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-15.100MRQ-0.229-14.871
MRQ-0.229TTM-0.867+0.638
TTM-0.867YOY-2.793+1.926
TTM-0.8675Y-4.189+3.322
5Y-4.18910Y-12.189+8.000
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD-15.100-2.973-12.127
MRQ-0.229-3.333+3.104
TTM-0.867-3.553+2.686
YOY-2.793-5.605+2.812
5Y-4.189-8.376+4.187
10Y-12.189-8.865-3.324
2. Book Value per Share
2.3. Price to Book Ratio

Measures if the stock price of Pieris is to cheap or to expensive compared to its book value.

  • At or below 1 is considered healthy (always compare to Biotechnology industry mean).
  • A PB ratio of 0.67 means the investor is paying $0.67 for each $1 in book value.

Let's take a look of the Price to Book Ratio trends of Pieris Pharmaceuticals Inc:

  • The EOD is 44.369. Based on the equity, the company is expensive. -2
  • The MRQ is 0.673. Based on the equity, the company is cheap. +2
  • The TTM is 2.071. Based on the equity, the company is underpriced. +1
Trends
Current periodCompared to+/- 
EOD44.369MRQ0.673+43.696
MRQ0.673TTM2.071-1.398
TTM2.071YOY4.157-2.086
TTM2.0715Y6.919-4.848
5Y6.91910Y13.296-6.377
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD44.3691.896+42.473
MRQ0.6732.115-1.442
TTM2.0712.093-0.022
YOY4.1572.884+1.273
5Y6.9193.542+3.377
10Y13.2963.916+9.380
2. Total Gains per Share

3. Holders & Insider Transactions

Let's take a look at which institutions, funds and insiders are holding shares of Pieris Pharmaceuticals Inc.

3.1. Institutions holding Pieris Pharmaceuticals Inc

Institutions are holding 39.443% of the shares of Pieris Pharmaceuticals Inc.

DateNameTotal SharesTotal AssetsCurrent SharesChange%
2023-09-30Bvf Inc20.84920.16562060986300
2023-12-31Renaissance Technologies Corp1.07740.00031065007683716179.3161
2023-12-31BlackRock Inc1.04980103774700
2023-12-31Acadian Asset Management LLC0.97350.000796235800
2023-12-31Vanguard Group Inc0.91790907390-128150-12.3752
2023-12-31Geode Capital Management, LLC0.7703076144400
2023-12-31CM Management, LLC0.75870.109775000010060015.4912
2023-09-30Citadel Advisors Llc0.54190535637-1462220-73.1894
2023-12-31Northern Trust Corp0.2464024359210578376.7606
2023-12-31State Street Corporation0.2254022281900
2023-12-31Millennium Management LLC0.16860166685-58747-26.0597
2023-12-31Prudential Financial Inc0.1115011020000
2023-12-31Susquehanna International Group, LLP0.104201029711029710
2023-12-31Virtu Financial LLC0.09110.001390059900590
2023-12-31Citigroup Inc0.089608858500
2023-12-31Goldman Sachs Group Inc0.045804526622660100.2389
2023-12-31Two Sigma Investments LLC0.0414040914-1476-3.482
2023-12-31Bank of New York Mellon Corp0.040403994900
2023-12-31XTX Topco Ltd0.04010.001639689396890
2023-12-31Northstar Asset Management LLC /NJ/0.03950.006539065390650
Total 28.18270.285727859240-466050-1.7%

3.2. Funds holding Pieris Pharmaceuticals Inc

DateNameTotal SharesTotal AssetsCurrent SharesChange%
2024-02-29Vanguard Institutional Extnd Mkt Idx Tr0.8950.000188550200
2024-02-29Fidelity Extended Market Index0.51790.0002512413-2483-0.4822
2023-12-31NT Ext Equity Mkt Idx Fd - NL0.16740.0005165662105783176.6613
2023-12-31NT Ext Equity Mkt Idx Fd - DC - NL - T20.13450.000513305085049177.1817
2023-09-30BlackRock Extended Mkt Composite0.13070.000312928200
2024-03-31BlackRock Extended Equity Market K0.1140.0001112828410.0364
2024-02-29Fidelity Total Market Index0.1018010066800
2024-02-29Fidelity Series Total Market Index0.087808690800
2023-12-31Northern Trust Extended Eq Market Idx0.07140.00027064300
2023-12-31NT Ext Equity Mkt Idx Fd - L0.07140.00027064300
2023-12-31SSgA U.S. Extended Market Index Class I0.03160.00023130000
2024-03-31State St US Extended Mkt Indx NL Cl C0.03160.00033130000
2024-02-29Spartan Total Market Index Pool E0.028802849100
2024-02-29Fidelity Nasdaq Composite Index0.022702248300
2024-02-29Vanguard U.S. Eq Idx £ Acc0.022102188800
2024-02-29Spartan Extended Market Index Pool E0.02130.000121102248313.3358
2024-03-31BlackRock U.S. Equity Market F0.01560154641490.9729
2024-03-31Extended Equity Market Fund M0.01410.000113918-28-0.2008
2023-12-31SSgA U.S. Total Market Index Strategy0.009109028-209-2.2626
2023-12-31NT US Market Cap Idx Fd - L0.00710703700
Total 2.49590.00282469610+190785+7.7%

3.3. Insider Transactions

Insiders are holding 7.447% of the shares of Pieris Pharmaceuticals Inc.

DateOwnerTypeAmountPricePost Transaction AmountLink
2023-05-25Christopher P KiritsyBUY100000.85

4. Summary

4.1. Key Performance Indicators

The key performance indicators of Pieris Pharmaceuticals Inc compared to the Most Recent Quarter (MRQ).

 End of day+/-Most Recent QuarterTrailing 12 Months+/-Year-Over-Year+/-5 Year+/-10 Year+/-
Book Value Change Per Share---0.038-0.003-92%-0.058+51%-0.007-83%0.007-665%
Book Value Per Share--0.2700.286-6%0.408-34%0.383-29%0.310-13%
Current Ratio--3.2442.159+50%2.435+33%2.986+9%3.950-18%
Debt To Asset Ratio--0.3080.536-42%0.642-52%0.652-53%1.578-80%
Debt To Equity Ratio--0.4461.719-74%1.833-76%2.257-80%2.447-82%
Dividend Per Share----0%-0%-0%-0%
Eps---0.046-0.062+34%-0.084+82%-0.086+85%-0.066+42%
Free Cash Flow Per Share---0.199-0.137-31%-0.157-21%-0.115-42%-0.054-73%
Free Cash Flow To Equity Per Share---0.199-0.036-82%-0.139-30%-0.024-88%6.241-103%
Gross Profit Margin--1.0001.0000%1.0000%1.0000%1.0000%
Intrinsic Value_10Y_max---5.051--------
Intrinsic Value_10Y_min---5.936--------
Intrinsic Value_1Y_max---0.257--------
Intrinsic Value_1Y_min---0.453--------
Intrinsic Value_3Y_max---0.961--------
Intrinsic Value_3Y_min---1.491--------
Intrinsic Value_5Y_max---1.895--------
Intrinsic Value_5Y_min---2.666--------
Market Cap1186222848.000+98%18006174.55040075879.742-55%175214999.840-90%242640170.092-93%270914401.278-93%
Net Profit Margin---3.529-2.560-27%-1.440-59%-2.151-39%114.960-103%
Operating Margin---4.220-2.782-34%-2.062-51%-2.283-46%115.232-104%
Operating Ratio--5.2203.803+37%2.820+85%3.232+61%-74.843+1534%
Pb Ratio44.369+98%0.6732.071-68%4.157-84%6.919-90%13.296-95%
Pe Ratio-64.748-6493%-0.982-0.617-37%-6.310+543%-9.041+821%-24.250+2369%
Price Per Share12.000+98%0.1820.405-55%1.773-90%2.455-93%2.741-93%
Price To Free Cash Flow Ratio-15.100-6493%-0.229-0.867+279%-2.793+1120%-4.189+1729%-12.189+5222%
Price To Total Gains Ratio-314.277-6493%-4.767-3.700-22%16.114-130%-1.278-73%-12.563+164%
Quick Ratio--3.4702.202+58%2.787+25%3.452+1%4.177-17%
Return On Assets---0.119-0.101-15%-0.068-42%-0.075-37%-2.292+1834%
Return On Equity---0.171-0.306+78%-0.198+15%-0.250+46%-0.264+54%
Total Gains Per Share---0.038-0.003-92%-0.058+51%-0.007-83%0.007-665%
Usd Book Value--26758000.00028306000.000-5%40377750.000-34%37856850.000-29%30653250.025-13%
Usd Book Value Change Per Share---0.038-0.003-92%-0.058+51%-0.007-83%0.007-665%
Usd Book Value Per Share--0.2700.286-6%0.408-34%0.383-29%0.310-13%
Usd Dividend Per Share----0%-0%-0%-0%
Usd Eps---0.046-0.062+34%-0.084+82%-0.086+85%-0.066+42%
Usd Free Cash Flow---19656000.000-13497500.000-31%-15497750.000-21%-11407050.000-42%-5291653.250-73%
Usd Free Cash Flow Per Share---0.199-0.137-31%-0.157-21%-0.115-42%-0.054-73%
Usd Free Cash Flow To Equity Per Share---0.199-0.036-82%-0.139-30%-0.024-88%6.241-103%
Usd Market Cap1186222848.000+98%18006174.55040075879.742-55%175214999.840-90%242640170.092-93%270914401.278-93%
Usd Price Per Share12.000+98%0.1820.405-55%1.773-90%2.455-93%2.741-93%
Usd Profit---4584000.000-5918000.000+29%-7187500.000+57%-8024350.000+75%-6214783.775+36%
Usd Revenue--1299000.00010702500.000-88%6475500.000-80%8786600.000-85%6096596.900-79%
Usd Total Gains Per Share---0.038-0.003-92%-0.058+51%-0.007-83%0.007-665%
 EOD+5 -3MRQTTM+11 -22YOY+14 -195Y+10 -2310Y+10 -23

4.2. Fundamental Score

Let's check the fundamental score of Pieris Pharmaceuticals Inc based on Penke's default stock scanner.

Penke's Stock Scanner

  
  
IndicatorConditionValue
Price to Earnings Ratio (EOD)Between0-15-64.748
Price to Book Ratio (EOD)Between0-144.369
Net Profit Margin (MRQ)Greater than0-3.529
Operating Margin (MRQ)Greater than0-4.220
Quick Ratio (MRQ)Greater than13.470
Current Ratio (MRQ)Greater than13.244
Debt to Asset Ratio (MRQ)Less than10.308
Debt to Equity Ratio (MRQ)Less than10.446
Return on Equity (MRQ)Greater than0.15-0.171
Return on Assets (MRQ)Greater than0.05-0.119
Total4/10 (40.0%)

4.3. Technical Score

Let's check the technical score of Pieris Pharmaceuticals Inc based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5099.611
Ma 20Greater thanMa 500.763
Ma 50Greater thanMa 1000.410
Ma 100Greater thanMa 2000.292
OpenGreater thanClose11.420
Total4/5 (80.0%)



Reversals in quarterly reports

I have detected a reversal (positive to negative, negative to positive) in the following values of the quarterly reports.

 2022-12-312023-03-312023-06-302023-09-302023-12-31
Accumulated Other Comprehensive Income  -254-172-426289-137-202-33936728
Depreciation and Amortization  3,391-1,3632,028-1,303725-17708-931-223



Latest Balance Sheet

Balance Sheet of 2023-12-31. All numbers in thousands.

Summary
Total Assets38,680
Total Liabilities11,922
Total Stockholder Equity26,758
 As reported
Total Liabilities 11,922
Total Stockholder Equity+ 26,758
Total Assets = 38,680

Assets

Total Assets38,680
Total Current Assets38,680
Long-term Assets0
Total Current Assets
Cash And Cash Equivalents 17,396
Short-term Investments 8,970
Net Receivables 6,039
Other Current Assets 6,275
Total Current Assets  (as reported)38,680
Total Current Assets  (calculated)38,680
+/-0
Long-term Assets
Long-term Assets  (as reported)0
Long-term Assets  (calculated)0
+/-0

Liabilities & Shareholders' Equity

Total Current Liabilities11,922
Long-term Liabilities0
Total Stockholder Equity26,758
Total Current Liabilities
Accounts payable 3,372
Other Current Liabilities 8,550
Total Current Liabilities  (as reported)11,922
Total Current Liabilities  (calculated)11,922
+/-0
Long-term Liabilities
Long-term Liabilities  (as reported)0
Long-term Liabilities  (calculated)0
+/-0
Total Stockholder Equity
Common Stock98
Retained Earnings -314,964
Accumulated Other Comprehensive Income 28
Other Stockholders Equity 341,596
Total Stockholder Equity (as reported)26,758
Total Stockholder Equity (calculated)26,758
+/-0
Other
Cash and Short Term Investments 26,366
Common Stock Shares Outstanding 98,935
Liabilities and Stockholders Equity 38,680
Net Debt -17,396
Net Working Capital 26,758



Balance Sheet

All numbers in thousands.

 Trend2023-12-312023-09-302023-06-302023-03-312022-12-312022-09-302022-06-302022-03-312021-12-312021-09-302021-06-302021-03-312020-12-312020-09-302020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312018-12-312018-09-302018-06-302018-03-312017-12-312017-09-302017-06-302017-03-312016-12-312016-09-302016-06-302016-03-312015-12-312015-09-302015-06-302015-03-312014-12-312014-09-302014-06-302014-03-312013-12-312013-09-30
> Total Assets 
0
0
0
11
0
21,900
16,775
14,478
36,201
33,950
37,205
46,455
43,713
35,063
61,875
105,957
98,861
103,876
173,239
162,025
151,657
141,341
131,048
130,840
116,751
141,097
123,773
117,783
115,724
105,010
115,786
155,030
164,184
153,560
137,115
114,309
99,163
95,490
82,258
87,544
59,376
38,680
38,68059,37687,54482,25895,49099,163114,309137,115153,560164,184155,030115,786105,010115,724117,783123,773141,097116,751130,840131,048141,341151,657162,025173,239103,87698,861105,95761,87535,06343,71346,45537,20533,95036,20114,47816,77521,900011000
   > Total Current Assets 
0
0
0
11
0
19,800
14,965
12,642
34,151
31,661
34,867
43,880
41,137
32,673
58,756
102,743
95,276
89,790
166,081
156,599
146,849
135,382
124,286
111,462
97,973
115,013
98,372
92,028
88,658
75,721
88,272
127,673
137,647
127,625
111,749
90,904
78,560
73,424
60,505
66,472
59,089
38,680
38,68059,08966,47260,50573,42478,56090,904111,749127,625137,647127,67388,27275,72188,65892,02898,372115,01397,973111,462124,286135,382146,849156,599166,08189,79095,276102,74358,75632,67341,13743,88034,86731,66134,15112,64214,96519,800011000
       Cash And Cash Equivalents 
0
0
0
11
0
18,500
13,167
10,027
32,255
29,349
31,189
40,374
36,558
29,356
55,242
50,325
89,921
37,878
109,521
50,576
89,482
74,867
52,094
54,901
46,068
62,260
47,431
44,302
66,890
70,436
66,835
119,097
125,052
117,764
83,737
54,257
48,423
38,635
39,742
44,938
32,894
17,396
17,39632,89444,93839,74238,63548,42354,25783,737117,764125,052119,09766,83570,43666,89044,30247,43162,26046,06854,90152,09474,86789,48250,576109,52137,87889,92150,32555,24229,35636,55840,37431,18929,34932,25510,02713,16718,500011000
       Short-term Investments 
0
72
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
34,751
50,061
100,399
47,822
53,240
58,685
44,782
40,175
41,894
39,333
32,912
15,750
0
0
0
0
0
16,531
26,679
21,400
20,534
8,637
9,937
11,916
8,970
8,97011,9169,9378,63720,53421,40026,67916,5310000015,75032,91239,33341,89440,17544,78258,68553,24047,822100,39950,06134,751000000000000000720
       Net Receivables 
0
0
0
0
0
15
15
16
21
981
70
58
58
58
39
48,470
2,537
15,546
3,309
2,559
5,338
2,701
7,128
7,174
6,952
6,787
7,267
10,712
2,944
1,706
15,810
2,803
6,646
3,313
1,644
1,264
829
5,810
1,055
952
3,029
6,039
6,0393,0299521,0555,8108291,2641,6443,3136,6462,80315,8101,7062,94410,7127,2676,7876,9527,1747,1282,7015,3382,5593,30915,5462,53748,47039585858709812116151500000
       Other Current Assets 
0
511
0
0
0
1,300
1,783
2,598
1,875
2,311
3,608
3,506
4,580
3,260
3,475
3,948
2,818
1,615
3,190
3,065
4,207
4,574
6,379
4,605
4,778
4,072
4,341
4,102
3,074
3,579
5,627
5,773
5,949
6,548
9,837
8,704
7,908
8,445
11,071
10,645
9,152
6,275
6,2759,15210,64511,0718,4457,9088,7049,8376,5485,9495,7735,6273,5793,0744,1024,3414,0724,7784,6056,3794,5744,2073,0653,1901,6152,8183,9483,4753,2604,5803,5063,6082,3111,8752,5981,7831,3000005110
   > Long-term Assets 
0
0
0
0
0
2,100
1,809
1,836
2,050
2,290
2,338
2,574
2,575
2,390
3,119
3,213
3,585
14,086
7,158
5,426
4,808
5,959
6,762
19,378
18,778
26,084
25,401
25,755
27,066
29,289
27,514
27,357
26,537
25,935
25,366
23,405
20,603
22,066
21,753
21,072
287
0
028721,07221,75322,06620,60323,40525,36625,93526,53727,35727,51429,28927,06625,75525,40126,08418,77819,3786,7625,9594,8085,4267,15814,0863,5853,2133,1192,3902,5752,5742,3382,2902,0501,8361,8092,10000000
       Property Plant Equipment 
0
2,438
0
0
0
2,100
1,786
1,811
1,928
2,163
2,210
2,447
2,448
2,264
2,993
3,085
3,456
4,034
4,445
4,597
4,687
5,049
4,893
7,888
11,008
22,938
23,514
23,780
25,073
25,980
24,301
24,234
23,587
23,031
22,693
21,047
19,296
20,697
20,502
19,979
1,984
0
01,98419,97920,50220,69719,29621,04722,69323,03123,58724,23424,30125,98025,07323,78023,51422,93811,0087,8884,8935,0494,6874,5974,4454,0343,4563,0852,9932,2642,4482,4472,2102,1631,9281,8111,7862,1000002,4380
       Long Term Investments 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
9,922
2,583
700
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
00000000000000000000007002,5839,92200000000000000000
       Other Assets 
0
19
0
0
0
27
24
25
121
127
128
127
128
126
126
129
129
10,052
130
129
121
910
1,869
11,490
7,770
3,146
1,887
1,975
5,671
7,243
3,213
3,123
2,950
2,904
2,673
2,358
1,307
1,369
0
1,093
0
0
001,09301,3691,3072,3582,6732,9042,9503,1233,2137,2435,6711,9751,8873,1467,77011,4901,86991012112913010,052129129126126128127128127121252427000190
       Deferred Long Term Asset Charges 
0
0
0
0
0
27
24
24
24
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0000000000000000000000000000000002424242700000
> Total Liabilities 
0
3
3
1
1
3,900
2,547
3,330
2,550
2,822
10,029
9,163
12,230
9,836
43,839
96,623
94,303
92,354
122,546
106,707
101,396
101,406
100,886
111,355
96,109
89,745
73,967
71,111
72,033
73,983
77,550
108,309
110,331
102,805
83,665
69,944
63,396
67,561
66,800
47,046
28,866
11,922
11,92228,86647,04666,80067,56163,39669,94483,665102,805110,331108,30977,55073,98372,03371,11173,96789,74596,109111,355100,886101,406101,396106,707122,54692,35494,30396,62343,8399,83612,2309,16310,0292,8222,5503,3302,5473,90011330
   > Total Current Liabilities 
0
3
3
1
1
3,500
2,251
3,022
2,242
2,798
6,498
6,419
9,952
8,380
11,445
35,796
39,038
45,775
54,763
52,334
40,594
48,076
41,125
40,928
39,848
27,003
20,483
18,260
19,687
22,145
30,265
43,928
49,696
50,561
39,484
35,546
33,521
36,583
42,875
34,369
28,866
11,922
11,92228,86634,36942,87536,58333,52135,54639,48450,56149,69643,92830,26522,14519,68718,26020,48327,00339,84840,92841,12548,07640,59452,33454,76345,77539,03835,79611,4458,3809,9526,4196,4982,7982,2423,0222,2513,50011330
       Short-term Debt 
0
0
2
0
0
1,271
0
0
0
0
0
0
0
0
0
0
0
4,862
4,053
2,783
5,209
8,169
7,877
7,423
6,134
733
851
881
934
1,030
987
959
1,032
1,049
1,003
914
826
859
890
910
12,292
0
012,2929108908598269141,0031,0491,0329599871,0309348818517336,1347,4237,8778,1695,2092,7834,0534,862000000000001,27100200
       Short Long Term Debt 
0
0
0
0
0
1,271
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0000000000000000000000000000000000001,27100000
       Accounts payable 
0
1
3
1
1
1,300
1,540
2,058
1,118
1,059
1,711
1,638
4,524
2,386
3,317
4,646
2,602
2,452
1,934
3,174
2,693
3,350
3,728
4,031
5,436
10,054
5,188
5,682
3,429
3,007
6,933
6,525
6,294
8,609
5,652
2,902
3,641
4,154
5,833
9,135
4,164
3,372
3,3724,1649,1355,8334,1543,6412,9025,6528,6096,2946,5256,9333,0073,4295,6825,18810,0545,4364,0313,7283,3502,6933,1741,9342,4522,6024,6463,3172,3864,5241,6381,7111,0591,1182,0581,5401,30011310
       Other Current Liabilities 
0
3
1
0
0
2,200
711
964
1,124
1,739
2,322
2,325
2,898
3,719
2,959
6,351
5,100
1,308
2,525
1,779
772
945
1,339
1,068
1,036
4,960
4,400
3,785
5,279
5,481
5,109
10,908
15,921
15,787
11,916
8,867
10,556
10,746
9,464
6,641
11,416
8,550
8,55011,4166,6419,46410,74610,5568,86711,91615,78715,92110,9085,1095,4815,2793,7854,4004,9601,0361,0681,3399457721,7792,5251,3085,1006,3512,9593,7192,8982,3252,3221,7391,1249647112,20000130
   > Long-term Liabilities 
0
2
2
1
1
400
296
308
308
24
3,531
2,744
2,278
1,456
32,395
60,827
55,265
46,579
67,783
54,373
60,802
53,330
59,761
70,427
56,261
62,742
53,484
52,851
52,346
51,838
47,285
64,381
60,635
52,244
44,181
34,398
29,875
30,978
23,925
12,677
0
0
0012,67723,92530,97829,87534,39844,18152,24460,63564,38147,28551,83852,34652,85153,48462,74256,26170,42759,76153,33060,80254,37367,78346,57955,26560,82732,3951,4562,2782,7443,5312430830829640011220
       Deferred Long Term Asset Charges 
0
0
0
0
0
27
24
24
24
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0000000000000000000000000000000002424242700000
       Other Liabilities 
0
380
0
0
0
334
296
308
308
24
3,531
2,744
2,279
1,456
32,394
60,827
55,265
46,579
67,783
54,373
60,802
53,330
59,761
70,427
56,261
47,258
38,560
37,845
36,919
35,906
32,315
49,421
46,190
38,403
30,819
22,063
18,484
18,734
0
759
0
0
00759018,73418,48422,06330,81938,40346,19049,42132,31535,90636,91937,84538,56047,25856,26170,42759,76153,33060,80254,37367,78346,57955,26560,82732,3941,4562,2792,7443,531243083082963340003800
       Deferred Long Term Liability 
0
0
0
0
0
0
0
0
0
0
3,492
2,702
2,234
1,409
32,353
60,784
55,222
46,542
67,746
54,336
60,770
53,303
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0000000000000000000053,30360,77054,33667,74646,54255,22260,78432,3531,4092,2342,7023,4920000000000
> Total Stockholder Equity
0
-3
-3
10
-1
18,000
14,227
11,147
33,651
31,128
27,176
37,292
31,482
25,227
18,036
9,334
4,558
11,522
50,693
55,318
50,261
39,935
30,162
19,485
20,642
51,352
49,806
46,672
43,691
31,027
38,236
46,721
53,853
50,755
53,450
44,365
35,767
27,929
15,458
40,498
30,510
26,758
26,75830,51040,49815,45827,92935,76744,36553,45050,75553,85346,72138,23631,02743,69146,67249,80651,35220,64219,48530,16239,93550,26155,31850,69311,5224,5589,33418,03625,22731,48237,29227,17631,12833,65111,14714,22718,000-110-3-30
   Common Stock
0
5
5
6
6
29
29
29
40
40
40
43
43
43
43
44
45
45
54
54
54
54
49
49
49
55
55
52
56
56
60
67
72
72
74
74
74
74
74
99
99
98
9899997474747474727267605656525555494949545454544545444343434340404029292966550
   Retained Earnings Total Equity00-299,628-303,6040-282,319-272,583-262,245-257,144-247,612-231,076-215,578-211,406-197,006-182,723-177,773-174,176-173,405-170,813-159,055-147,066-135,384-129,229-129,026-120,312-127,802-120,743-110,659-102,665-96,106-89,910-84,027-79,866-76,964-73,042-69,512-65,807-30-16-10-80
   Accumulated Other Comprehensive Income 
0
0
0
0
0
-1,600
-1,446
-1,344
-1,150
-1,273
-1,432
-1,326
-1,325
-1,501
-1,451
-2,093
-2,487
-4,695
-5,973
-2,574
-3,053
-2,982
-2,056
-2,707
-697
-1,995
-1,227
-1,064
-782
-295
194
234
616
829
953
625
524
-254
-426
-137
-339
28
28-339-137-426-254524625953829616234194-295-782-1,064-1,227-1,995-697-2,707-2,056-2,982-3,053-2,574-5,973-4,695-2,487-2,093-1,451-1,501-1,325-1,326-1,432-1,273-1,150-1,344-1,446-1,60000000
   Capital Surplus 
0
0
0
20
20
84,627
85,156
85,503
111,725
112,227
112,595
128,484
128,871
129,350
130,102
132,126
134,803
136,484
185,638
187,067
188,644
189,929
191,224
192,956
194,695
227,468
228,751
230,407
241,423
242,672
253,560
277,496
302,591
306,998
314,668
316,249
317,488
0
319,414
340,164
0
0
00340,164319,4140317,488316,249314,668306,998302,591277,496253,560242,672241,423230,407228,751227,468194,695192,956191,224189,929188,644187,067185,638136,484134,803132,126130,102129,350128,871128,484112,595112,227111,72585,50385,15684,6272020000
   Treasury Stock000000000000000000000000000000000000000000
   Other Stockholders Equity 
0
0
0
20
23
85,371
85,156
85,503
111,725
112,227
112,595
128,484
128,871
129,350
130,102
132,126
134,803
136,484
185,638
187,067
188,644
189,929
191,224
192,956
194,695
227,468
228,751
230,407
241,423
242,672
253,560
277,496
300,777
306,998
314,668
316,249
317,488
318,530
319,414
340,164
341,130
341,596
341,596341,130340,164319,414318,530317,488316,249314,668306,998300,777277,496253,560242,672241,423230,407228,751227,468194,695192,956191,224189,929188,644187,067185,638136,484134,803132,126130,102129,350128,871128,484112,595112,227111,72585,50385,15685,3712320000



Balance Sheet

All numbers in thousands.




Cash Flow

Currency in USD. All numbers in thousands.




Income Statement

Currency in USD. All numbers in thousands.


Latest Income Statement (annual, 2023-12-31)

Gross Profit (+$)
totalRevenue42,810
Cost of Revenue-1,781
Gross Profit41,02941,029
 
Operating Income (+$)
Gross Profit41,029
Operating Expense-56,873
Operating Income-15,844-15,844
 
Operating Expense (+$)
Research Development40,020
Selling General Administrative16,853
Selling And Marketing Expenses0
Operating Expense56,87356,873
 
Net Interest Income (+$)
Interest Income1,747
Interest Expense-0
Other Finance Cost-0
Net Interest Income1,747
 
Pretax Income (+$)
Operating Income-15,844
Net Interest Income1,747
Other Non-Operating Income Expenses0
Income Before Tax (EBT)-24,543-7,145
EBIT - interestExpense = -15,844
-24,543
-24,543
Interest Expense0
Earnings Before Interest and Taxes (EBIT)-15,844-24,543
Earnings Before Interest and Taxes (EBITDA)-14,063
 
After tax Income (+$)
Income Before Tax-24,543
Tax Provision-0
Net Income From Continuing Ops-28,061-24,543
Net Income-24,543
Net Income Applicable To Common Shares0
 
Non-recurring Events
Discontinued Operations0
Extraordinary Items0
Effect of Accounting Charges0
Other Items0
Non Recurring0
Other Operating Expenses58,654
Total Other Income/Expenses Net-8,699-1,747
 

Technical Analysis of Pieris
The psychology behind the price

Technical indicators reflecting market sentiment and the collective psychology of you and other traders. Your emotions and other traders' emotions, such as fear and greed, play a significant role in driving price movements.

General trend

First of all, I'm going to put something in the back of your mind. One of the most stable factors that gives you more confidence as a trader: the general trend of Pieris. The general trend of Pieris is BULLISH with 100.0% confidence. It is very important for your mental being to use each indicator with this in mind. But beware, also the general trend flips once in a while! You can use moving averages to determine Pieris's overall trend. For convenience I use the most commonly used moving averages: 20, 50, 100 & 200. Of course you can use other moving averages or other indicators to determine the trend.

Indicator phases

Some of the indicators I use have 3 zones: overbought, oversold and neutral. Transitions between these zones (market phases) provide valuable trading signals and insights. Expecially with the general trend mind, I use the highlighted phases:

Indicator zone transitionsBullish trend (100.0%) Bearish trend (-100.0%)
Overbought to neutralBullish pullback=Bearish reversal
Upper to lower neutralBullish correction=Bearish continuation
Nuetral to oversoldOversold=Oversold
Oversold to neutralBullish reversal=Bearish correction
Lower to upper neutralBullish continuation=Bearish pullback
Nuetral to overboughtOverbought=Overbought

1. Price Targets

1.1 Support & Resistance

Support and resistance are levels on a price chart that act as barriers or zones where the price of an asset tends to stop, reverse, or experience a significant amount of buying or selling pressure.

Support is a price level at which demand for an asset is strong enough to prevent the price from falling further.
Resistance is a price level at which selling pressure becomes significant enough to prevent the price of an asset from rising further.


Score

Let's take a look at the Support & Resistance of Pieris Pharmaceuticals Inc.

The long score for the Support & Resistance is 0/1.
The longshort score for the Support & Resistance is 0/(-1 +1).

  • Between support/resistance: The price is trading between support and resistance lines.

The bullish price targets are: .

The bearish price targets are: 2.115 > 2.1089 > 1.975.

Tweet this
Pieris Pharmaceuticals Inc Daily Support & Resistance Chart

2. Trend Indicators

2.1 Moving Averages

Shows the moving average of the selected period.

  • Moving averages are lagging trend indicators.
  • There are many types of moving averages.
  • Moving averages are also used within other indicators.

Score

Let's take a look at the Moving Averages of Pieris Pharmaceuticals Inc. The current mas is .

The long score for the Moving Averages is 14/14.
The longshort score for the Moving Averages is 14/(-14 +14).

  • MA 20 trending up: The MA 20 is trending up. +1
  • Close > MA 20: The price is above the MA 20. +1
  • MA 20 > MA 50: The MA 20 is higher than the MA 50. +1
  • MA 20 > MA 100: The MA 20 is higher than the MA 100. +1
  • MA 20 > MA 200: The MA 20 is higher than the MA 200. +1
  • MA 50 trending up: The MA 50 is trending up. +1
  • Close > MA 50: The price is above the MA 50. +1
  • MA 50 > MA 100: The MA 50 is higher than the MA 100. +1
  • MA 50 > MA 200: The MA 50 is higher than the MA 200. +1
  • MA 100 trending up: The MA 100 is trending up. +1
  • Close > MA 100: The price is above the MA 100. +1
  • MA 100 > MA 200: The MA 100 is higher than the MA 200. +1
  • MA 200 trending up: The MA 200 is trending up. +1
  • Close > MA 200: The price is above the MA 200. +1

Directionalities and relatives.

Moving AverageAmount of candlesTrendPrice +/-vs. MA 50vs. MA 100vs. MA 200
MA 2020
MA 5050-
MA 100100--
MA 200200---

Explanation: https://www.youtube.com/watch?v=xwW8h0lrQ-I

Pieris Pharmaceuticals Inc Daily Moving Averages Chart
2.2 Moving Average Convergence/Divergence (MACD)

Shows the momentum of the selected period based on two moving averages.

  • MACD is a lagging momentum indicator.
  • Uses two moving averages.
  • Can show buy or sell signals based on momentum.
  • Can show overbought. and oversold. levels.

Score

Let's take a look at the Moving Average Convergence/Divergence (MACD) of Pieris Pharmaceuticals Inc. The current macd is 0.93727851.

The long score for the Moving Average Convergence/Divergence (MACD) is 4/4.
The longshort score for the Moving Average Convergence/Divergence (MACD) is 4/(-4 +4).

  • MACD line > signal line: The MACD line is above the signal line, which indicates a bullish signal in the market. This means that the positive momentum is currently stronger than the average momentum, suggesting that buyers are more active than sellers, and there's a higher probability of the Pieris price going up in the near term. +2
  • MACD > 0: The MACD is above the zero line (centerline), it indicates a bullish signal for Pieris. This means that the short-term moving average is higher than the long-term moving average, signaling positive momentum and suggesting a higher likelihood of the Pieris price continuing to rise in the near future. It indicates that buyers are gaining control, and there is optimism in the market, leading to potential price increases. +1
  • Trending up: The MACD line is trending up. This indicates that the short-term moving average is rising faster than the long-term moving average, suggesting positive momentum in the market. This signals that buyers are becoming more active and confident, leading to potential price increases as traders anticipate further gains and are willing to buy at higher prices. +1
Pieris Pharmaceuticals Inc Daily Moving Average Convergence/Divergence (MACD) ChartPieris Pharmaceuticals Inc Daily Moving Average Convergence/Divergence (MACD) Chart
2.3 Directional Movement Index (DMI)

The DMI is a collection of 3 indicators: +DI (Plus Direction Indicator), -DI (Minus Direction Indicator) and ADX (Average Directional Index). The ADX helps you determine the strength of a trend.


Score

Let's take a look at the Directional Movement Index (DMI) of Pieris Pharmaceuticals Inc. The current adx is 26.31.

The long score for the Directional Movement Index (DMI) is 4/7.
The longshort score for the Directional Movement Index (DMI) is 4/(-7 +7).

  • PLUS_ID > MINUS_DI: The +DI line is above the -DI line. This indicates a bullish signal in the market, as the positive directional movement is currently stronger than the negative directional movement, showing that buyers have the upper hand. Market psychology suggests that traders are optimistic, expecting further price increases, and are more willing to buy Pieris shares, leading to potential upward momentum in its price. +1
  • PLUS_ID > MINUS_DI && ADX > 25 && ADX trending up: The ADX is above 25 and indicates a strong bullish trend. The ADX is trending up, so the bullish trend is strengthening.
Pieris Pharmaceuticals Inc Daily Directional Movement Index (DMI) Chart
2.4 Parabolic SAR

Shows the current trend and potential entry and exit signals.

  • Parabolic SAR (stop and reverse) is a lagging trend indicator.
  • Shows the current trend.
  • Shows potential entry signals.
  • Shows  potential exit signals.
  • Can be used to place trailing stoplosses..

Score

Let's take a look at the Parabolic SAR of Pieris Pharmaceuticals Inc. The current sar is 0.138.

The long score for the Parabolic SAR is 1/1.
The longshort score for the Parabolic SAR is 1/(-1 +1).

  • Close > SAR: The price is above the SAR. It's generally considered a bullish signal. +1
Pieris Pharmaceuticals Inc Daily Parabolic SAR Chart

3. Momentum Indicators

3.1 Relative Strength Index (RSI)

Measures the speed and change of price movements.

  • Leading momentum indicator, meaning the signals are instant.
  • Ranges between 0 and 100.
  • Above 70 is considered overbought.
  • Below 30 is considered oversold.
  • Above or below 50 can also be used to determine price trend or support and resistance.
  • RSI divergence looks at a deviation between RSI and price movement. Penketrading automatically calculates RSI divergences.
  • Can be used in many different ways

Score

Let's take a look at the Relative Strength Index (RSI) of Pieris Pharmaceuticals Inc. The current rsi is 99.61. The current phase is Overbought in bull market.

The long score for the Relative Strength Index (RSI) is 1/13.
The longshort score for the Relative Strength Index (RSI) is 0/(-13 +13).

  • Overbought in bull market: Short-term excessive buying, potential for pullback. Consider taking profits, be cautious of potential correction. -1
  • Trending up: The RSI is trending up. +1
Pieris Pharmaceuticals Inc Daily Relative Strength Index (RSI) ChartPieris Pharmaceuticals Inc Daily Relative Strength Index (RSI) Chart
3.2 Stochastic Oscillator

Compares a certain price to multiple prices ranging over time.

  • Leading momentum indicator, meaning the signals are instant.
  • Used to determine overbought and oversold areas much like the RSI.
  • Ranges between 0 and 100.
  • Above 80 is considered overbought.
  • Below 20 is considered oversold.
  • Consists of two lines named K and D.
  • K compares the highest high and lowest low on the selected price range.
  • The D line is a moving average of the K line.
  • Can be used to spot divergences

Score

Let's take a look at the Stochastic Oscillator of Pieris Pharmaceuticals Inc. The current phase is Overbought in bull market.

The long score for the Stochastic Oscillator is 6/6.
The longshort score for the Stochastic Oscillator is 6/(-6 +6).

  • STOCH > 50: The STOCH %K is above 50. There are more buyers than sellers. +1
  • STOCH > 80: The STOCH %K is above 80 and overbought. +2
  • STOCH %K line > STOCH %D line: The STOCH %K line is above the STOCH %D line, which indicates a bullish signal in the market. This means that the positive momentum is currently stronger than the average momentum, suggesting that buyers are more active than sellers, and there's a higher probability of the Pieris price going up in the near term. +2
  • Trending up: The STOCH %K is trending up. +1
Pieris Pharmaceuticals Inc Daily Stochastic Oscillator ChartPieris Pharmaceuticals Inc Daily Stochastic Oscillator Chart
3.3 Commodity Channel Index (CCI)

Measures the difference between the current price and the historical average price.

  • Lagging or leading Momentum indicator
  • When the CCI is above zero, the price is above the historical average
  • When the CCI is below zero, the price is below the historical average
  • Used for spotting trends
    • If the CCI moves from negative or near zero to positive 100 that might indicate an uptrend
    • If the CCI moves from positive or near zero to negative -100 that might indicate a downtrend

Score

Let's take a look at the Commodity Channel Index (CCI) of Pieris Pharmaceuticals Inc. The current cci is 666.67.

The long score for the Commodity Channel Index (CCI) is 1/1.
The longshort score for the Commodity Channel Index (CCI) is 1/(-1 +1).

  • CCI > 100: The CCI is above 100, it indicates that the price is significantly above its average, suggesting a potential overbought condition. +1
Pieris Pharmaceuticals Inc Daily Commodity Channel Index (CCI) ChartPieris Pharmaceuticals Inc Daily Commodity Channel Index (CCI) Chart
3.4 Chande Momentum Oscillator (CMO)

Measures the difference between the sum of recent gains and the sum of recent losses. Then divides the result by the sum of all price movements in that period.

  • Lagging momentum indicator
  • Ranges between +100 and -100
  • Considered overbought above +50
  • Considered oversold below -50
  • It's possible to add a moving average that acts as a signal line

Score

Let's take a look at the Chande Momentum Oscillator (CMO) of Pieris Pharmaceuticals Inc. The current cmo is 99.50.

The long score for the Chande Momentum Oscillator (CMO) is 1/1.
The longshort score for the Chande Momentum Oscillator (CMO) is 1/(-1 +1).

  • CMO > 0: The CMO is above 0, the momentum of the price is positive, indicating a potential uptrend in the price. +1
Pieris Pharmaceuticals Inc Daily Chande Momentum Oscillator (CMO) ChartPieris Pharmaceuticals Inc Daily Chande Momentum Oscillator (CMO) Chart
3.5 Williams %R

 Shows the current price relative to the highest high over the last 14 days.
 

  • Lagging momentum indicator
  • Ranging between 0 and -100
  • Above -20 is considered overbought
  • Below -80 is considered oversold
  • Is prone to give false signals

Score

Let's take a look at the Williams %R of Pieris Pharmaceuticals Inc. The current willr is -7.27016886.

The long score for the Williams %R is 1/1.
The longshort score for the Williams %R is 1/(-1 +1).

  • WILLR > -20: The Williams %R is above -20. This indicates that the price is in overbought territory, suggesting a potential price correction or trend reversal to the downside. +1
Pieris Pharmaceuticals Inc Daily Williams %R ChartPieris Pharmaceuticals Inc Daily Williams %R Chart

4. Volatility Indicators

4.1 Bollinger Bands

Shows if the price is to high or to low relative to an average.

  • Lagging volatility indicator
  • Uses 3 bands: one upper, one lower and one in the middle
  • Works best when the middle band reflects an intermediate trend (MA20).
  • When the price is moving closer to the upper band, the market might be overbought
  • When the price is moving closer to the lower band, the market might be oversold 

Score

Let's take a look at the Bollinger Bands of Pieris Pharmaceuticals Inc.

Pieris Pharmaceuticals Inc Daily Bollinger Bands Chart
4.2 Average True Range (ATR)
Measures market volatility
  • Leading volatility indicator
  • Can be used to determine stop-loss positions
  • Calculated by:
    • Current high minus the current low
    • Current high minus the previous close
    • Current low minus the previous close
  • The larger the range of the candles, the greater the ATR value

Score

Let's take a look at the Average True Range (ATR) of Pieris Pharmaceuticals Inc. The current atr is 0.92739886.

Pieris Pharmaceuticals Inc Daily Average True Range (ATR) ChartPieris Pharmaceuticals Inc Daily Average True Range (ATR) Chart

5. Volume Indicators

5.1 On-Balance Volume (OBV)

 Measures market volatility

  • Leading momentum indicator
  • Calculation:
    • If the closing price is above the previous closing price: OBV = previous OBV + current volume
    • If the closing price is below the previous closing price: OBV = previous OBV - current volume
    • If the closing price is the same as the previous closing price than the OBV is the same.
  • Can be used to confirm price trends
  • Can be used with divergences

Score

Let's take a look at the On-Balance Volume (OBV) of Pieris Pharmaceuticals Inc. The current obv is 78,652,474.

Pieris Pharmaceuticals Inc Daily On-Balance Volume (OBV) ChartPieris Pharmaceuticals Inc Daily On-Balance Volume (OBV) Chart
5.2 Money Flow Index (MFI)

Measures the flow of money in and out of a security

  • Lagging momentum indicator
  • Looks like RSI but uses volume as an extra metric (RSI only considers price)
  • Above 80 is considered overbought
  • Below 20 is considered oversold
  • Can be used with divergences

Score

Let's take a look at the Money Flow Index (MFI) of Pieris Pharmaceuticals Inc. The current mfi is 55.79.

The long score for the Money Flow Index (MFI) is 1/2.
The longshort score for the Money Flow Index (MFI) is 1/(-2 +2).

  • MFI > 50: +1
Pieris Pharmaceuticals Inc Daily Money Flow Index (MFI) ChartPieris Pharmaceuticals Inc Daily Money Flow Index (MFI) Chart

6. Summary

6.1. Notifications

TypeNotificationDate
PenkeCurrently no notifications for Pieris Pharmaceuticals Inc.

6.2. Trading Signals

Below you will find trading signals as the indicator is commonly used. This doesn't mean you should use it that way. Learn from these, but don't use them blindly. I recommend using at least 4 indicators, 1 from each category: trend, momentum, volatility and volume.

DateIndicatorSignal
2023-11-30STOCH SHORT EXITThe %K line crosses above the %D line.
MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2023-12-01MFI LONG ENTRY SHORT CLOSE20 crossover to upside
2023-12-04CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2023-12-06STOCH LONG EXITThe %K line crosses below the %D line.
2023-12-07STOCH SHORT EXITThe %K line crosses above the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2023-12-11STOCH LONG EXITThe %K line crosses below the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2023-12-13STOCH SHORT EXITThe %K line crosses above the %D line.
2023-12-14RSI LONG ENTRY SHORT CLOSE30 crossover to upside
2023-12-18STOCH LONG EXITThe %K line crosses below the %D line.
2023-12-21SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
STOCH SHORT EXITThe %K line crosses above the %D line.
2023-12-22MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
2023-12-26CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2023-12-29STOCH LONG EXITThe %K line crosses below the %D line.
2024-01-02STOCH SHORT EXITThe %K line crosses above the %D line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-01-03STOCH LONG EXITThe %K line crosses below the %D line.
2024-01-04MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2024-01-05CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2024-01-08SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
2024-01-12DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-01-16DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-01-17WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-01-22STOCH SHORT EXITThe %K line crosses above the %D line.
2024-01-24STOCH LONG EXITThe %K line crosses below the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-01-26STOCH SHORT EXITThe %K line crosses above the %D line.
2024-01-29DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-01-31CCI LONG ENTRY SHORT CLOSE100 crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
2024-02-01STOCH LONG EXITThe %K line crosses below the %D line.
2024-02-06CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-02-08SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
2024-02-12MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-02-13DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2024-02-14STOCH SHORT EXITThe %K line crosses above the %D line.
2024-02-16DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-02-20STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-02-21MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
2024-02-22DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-02-26STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-02-27DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-02-28STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-02-29CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-03-01CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-03-05STOCH LONG EXITThe %K line crosses below the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2024-03-07STOCH SHORT EXITThe %K line crosses above the %D line.
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
2024-03-11STOCH LONG EXITThe %K line crosses below the %D line.
2024-03-12SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
2024-03-13STOCH SHORT EXITThe %K line crosses above the %D line.
2024-03-14STOCH LONG EXITThe %K line crosses below the %D line.
2024-03-15DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-03-18DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2024-03-19STOCH SHORT EXITThe %K line crosses above the %D line.
MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2024-03-20RSI SHORT ENTRY LONG CLOSE70 crossover to downside
STOCH LONG EXITThe %K line crosses below the %D line.
2024-03-22CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2024-03-25CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-03-26CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-03-27STOCH SHORT EXITThe %K line crosses above the %D line.
2024-03-28MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-04-01CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-04-02SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-04-09STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-04-10CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-04-11STOCH LONG EXITThe %K line crosses below the %D line.
2024-04-15STOCH SHORT EXITThe %K line crosses above the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2024-04-16STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-04-17DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2024-04-19STOCH SHORT EXITThe %K line crosses above the %D line.
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
2024-04-23MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).

6.3. Candlestick Patterns

Pieris Pharmaceuticals Inc Daily Candlestick Chart
DateCandlestick Pattern

6.4. Technical Score

Let's check the technical score of Pieris Pharmaceuticals Inc based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5099.611
Ma 20Greater thanMa 500.763
Ma 50Greater thanMa 1000.410
Ma 100Greater thanMa 2000.292
OpenGreater thanClose11.420
Total4/5 (80.0%)
Penke

Good job! You gained 25 XP and 0   0   10 . What's next:

  • Share my analysis of Pieris with someone you think should read this too:
  • Are you bullish or bearish on Pieris? Let me know what you think in the comments.
  • Do you want an email if I find something interesting about Pieris? Add an email alert using the form below.
  • Join the community if you want to keep your earnings and track your progress: Join the community
  • Is this analysis useful to you? Support me via But Me a Coffee. I'll analyze the stock market faster for you!

Get notifications about Pieris Pharmaceuticals Inc

I send you an email if I find something interesting about Pieris Pharmaceuticals Inc.


Comments

How you think about this?

Leave a comment

Stay informed about Pieris Pharmaceuticals Inc.

Receive notifications about Pieris Pharmaceuticals Inc in your mailbox!